A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Three Different Potency Levels of V181 (Dengue Quadrivalent Vaccine rDENV30 live, attenuated in Healthy Adults

Project: Research project

Project Details

StatusActive
Effective start/end date4/1/22 → 3/31/27

Funding

  • Merck Sharp and Cohme Corporation: $14,250.00